ANIPANI Pharmaceuticals, Inc.

$2B

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$64M+18.3% YoY

Gross Profit

$30M46.8% margin

Operating Income

-$19M-29.8% margin

Net Income

-$20M-31.2% margin

EPS (Diluted)

$-1.25

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$745M

Total Liabilities

$399M

Stockholders' Equity

$346M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$55M	+18.3%
Gross Profit	$30M	$35M	-12.5%
Operating Income	-$19M	$3M	-730.4%
Net Income	-$20M	$86,000	-23507.0%

Revenue Segments

Generics, Established Brands, and Other

$63M98%

Rare Disease

$1M2%

Geographic Segments

United States

$64M99%

Canada

$717,0001%

ANIP Q1 2022 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena